Episode Details

Back to Episodes
Scientists Found a New Way to Make Injured Optic Nerve Cells Regrow — Could It Help Restore Vision in Glaucoma?

Scientists Found a New Way to Make Injured Optic Nerve Cells Regrow — Could It Help Restore Vision in Glaucoma?

Published 1 week, 2 days ago
Description

This audio article is from VisualFieldTest.com.

Read the full article here: https://visualfieldtest.com/en/scientists-found-a-new-way-to-make-injured-optic-nerve-cells-regrow-could-it-help-restore-vision-in-glaucoma

Test your visual field online: https://visualfieldtest.com

Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support

Excerpt:

Scientists Found a New Way to Make Injured Optic Nerve Cells Regrow — Could It Help Restore Vision in Glaucoma? Short answer: The study offers a stronger explanation for how melanopsin can encourage injured retinal ganglion cells to grow axons: light-sensitive signaling through TRPC channels and cyclic adenosine monophosphate appears to work together. The results make the pathway more interesting as a research target, but they do not show that light exposure regrows a human optic nerve, that the new fibers reconnect correctly in the brain, or that vision returns in glaucoma. A reporting caveat matters here. The Proceedings of the National Academy of Sciences paper appeared online on October 27, 2026, and in the November 3, 2026 issue. Its accessible abstract describes the main findings but does not include the detailed axon counts, growth distances, sample sizes, exact statistical tests, or treatment schedule. I cannot verify those numbers from the available full-text record, so I will not invent them. Where possible, I distinguish the new paper from a related 2016 melanopsin study that does report additional experimental details. () What the November 2026 study tested The study used mice with an optic-nerve-crush injury, a laboratory model in which retinal ganglion cell axons are deliberately crushed. The researchers introduced OPN4, the gene for the light-sensitive protein melanopsin, into retinal ganglion cells. They then examined light responses in the cells and assessed axon growth after injury. The paper identifies the successfully infected cells as OPN4-expressing retinal ganglion cells. () The authors compared two broad groups of retinal ganglion cells: Alpha retinal ganglion cells: relatively large cells that include several distinct subtypes. Non-alpha retinal ganglion cells: the diverse remaining population—not one uniform cell type. They report that OPN4-expressing alpha cells produced both a fast, TRPC-dependent light response and a slower, cyclic adenosine monophosphate-dependent response. OPN4-expressing non-alpha cells showed mostly the fast response. The researchers then disrupted the relevant pathways genetically and tested whether supplying cell-permeant cyclic adenosine monophosphate could restore or increase regeneration. () This is more than a simple comparison of “gene therapy versus no gene therapy.” Removing the signaling components and then rescuing one of the effects with cyclic adenosine monophosphate provides evidence that the pathways matter to the reported growth response. It does not, by itself, establish that the resulting axons reconnect to the right brain circuits or restore vision. What the reported numbers do—and do not—show The paper’s accessible abstract reports the direction of the main effects, but not the underlying numerical data. In particular, it does not provide exact axon counts, farthest-growth distances, survival percentages, sample sizes, or p-values. Those numbers should be checked against the article’s figures and supporting information before being quoted. For the full table, please open this article on visualfieldtest.com. “Not stated in the abstract” is not the same as “the result was zero.” It means I cannot responsibly supply a numerical answer without verifying the full paper. The c

Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us